Study of Alzheimer's Disease Funding,Flows,and Beneficiary Populations in Different Co-morbidity States Based on SHA 2011
- VernacularTitle:基于"卫生费用核算体系2011"的不同共病状态下阿尔茨海默病的筹资、流向、受益人群研究
- Author:
Lanming FAN
1
;
Xiaoying WEI
;
Lian YANG
Author Information
1. 成都中医药大学管理学院 成都 611137
- Keywords:
Alzheimer's disease;
treatment cost;
age-adjusted charlson comorbidity;
SHA 2011
- From:
Chinese Health Economics
2024;43(6):59-63
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the current status of Alzheimer's disease(AD)treatment costs under different co-morbid states in Sichuan,and to provide references and basis for prioritizing the formulation of related health policies.Methods:Based on the System of Health Accounting 2011(SHA 2011).Results:The total treatment cost of Alzheimer's disease patients in Sichuan Province in 2019 was 277 280 400 yuan,accounting for 0.13%of the province's disease treatment cost in 2019.There were significant differences in treatment costs among different co-morbidity groups,with family health expenditure being the main financing option(54.44%).The higher the co-morbidity index,the greater the share of family health expenditure.Treatment costs mainly flowed to hospitals,with the proportion of treatment costs going to general hospitals gradually increasing as the co-morbidity index increased.The treatment cost of women is higher than that of men,and the treatment cost of low,middle and high co-morbidity groups were mainly concentrated in the age groups of 55～69,70～89 and 80 years old and above respectively.Conclusion:It is recommended to optimize the financing scheme and build a multi-level medical insurance system.Continuously improve the protection mechanism to narrow the difference in treatment between outpatient and inpatient;improve the service capacity of primary health care institutions;pay attention to key populations and do a good job of preventing AD,so as to alleviate the overall burden of Alzheimer's disease in China,and promote the realization of healthy aging.
